Patient Characteristics, Therapeutic Protocol, and Ablation Criteria
| Study | Age (y) | Histology | T | N | Stage | 131I activity (GBq) | TSH stimulation | TSH at time of 131I therapy | Ablation criteria for each study |
| Randolph (2002) | 49.5 (mean) | PTC (60%), FTC (28%), HCC (12%) | pT1–pT4 | N0 (64%), N1 (36%) | I–IVa | 1.1 | THW | 76 μIU/mL (mean) | NR |
| Hoyes (2004) | 51 (median) | PTC (60%), FTC (23%), HCC (17%) | NR | NR | NR | 3.5 | THW | NR | Uptake < 1% on 131I DxWBS |
| Bal (2006) | 37.9 (mean) | PTC (76%), FTC (24%) | NR | N0 | NR | 1.2 (mean) | THW | 11.7 μIU/mL (mean) | Uptake < 0.2% on 131I DxWBS and Tg < 10 ng/mL |
| Santra (2011) | 38 (mean) | PTC (78%), FTC (20%), HCC (6%) | NR | N0 | NR | 1.47 (mean) | THW | NR | Uptake < 0.2% on 131I DxWBS and Tg < 10 ng/mL |
| Giovanella (2013) | 44 (mean) | PTC (57%), follicular thyroid carcinoma (43%) | pT1 and pT2 | N0 | I–II | 1.1 (48%)–3.7 (52%) | THW | >25 μIU/mL in all patients | Negative 131I DxWBS and stimulated Tg < 2 ng/mL |
TSH = thyroid-stimulating hormone; PTC = papillary thyroid carcinoma; FTC = follicular thyroid carcinoma; HCC = hepatocellular carcinoma; THW = thyroid hormone withdrawal; NR = not reported; DxWBS = diagnostic radioiodine whole-body scintigraphy; Tg = thyroglobulin.
American Thyroid Association successful ablation criteria are negative imaging and either suppressed thyroglobulin < 0.2 ng/mL or TSH-stimulated thyroglobulin < 1 ng/mL (1)